4D Molecular Therapeutics Inc

詳細情報 4D Molecular Therapeutics Inc 企業名

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

企業情報

企業コードFDMT

会社名4D Molecular Therapeutics Inc

上場日Dec 11, 2020

最高経営責任者「CEO」Dr. David Kirn, M.D.

従業員数227

証券種類Ordinary Share

決算期末Dec 11

本社所在地5858 Horton Street #455

都市EMERYVILLE

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号94608

電話番号15105052680

ウェブサイトhttps://4dmoleculartherapeutics.com/

企業コードFDMT

上場日Dec 11, 2020

最高経営責任者「CEO」Dr. David Kirn, M.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. David Kirn, M.D.

Chief Executive Officer, Co-Founder, Director

1.66M

-0.02%

Dr. John F. Milligan, Ph.D.

Executive Chairman of the Board

100.00K

--

Dr. Fariborz (Fred) Kamal, Ph.D.

President, Chief Operating Officer

5.94K

--

Dr. Scott Bizily, J.D., Ph.D.

Chief Legal Officer and Corporate Secretary

--

Dr. Dhaval Desai, Pharm.D.

Chief Development Officer

--

Dr. Charles P. Theuer, M.D., Ph.D.

Independent Director

--

Ms. Nancy Miller-Rich

Independent Director

--

Dr. Jacob M. Chacko, M.D.

Independent Director

--

Mr. Christopher (Chris) Simms

Chief Commercial Officer

--

Dr. Robert (Bob) Kim, M.D.

Chief Medical Officer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. David Kirn, M.D.

Chief Executive Officer, Co-Founder, Director

1.66M

-0.02%

Dr. John F. Milligan, Ph.D.

Executive Chairman of the Board

100.00K

--

Dr. Fariborz (Fred) Kamal, Ph.D.

President, Chief Operating Officer

5.94K

--

Dr. Scott Bizily, J.D., Ph.D.

Chief Legal Officer and Corporate Secretary

--

Dr. Dhaval Desai, Pharm.D.

Chief Development Officer

--

Dr. Charles P. Theuer, M.D., Ph.D.

Independent Director

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

データなし

地域別USD

会社名

収益

比率

United States

14.00K

0.00%

Netherlands

0.00

0.00%

事業別

地域別

データなし

株主

更新時刻: 4 hours ago

株主統計

種類

株主統計

比率

BVF Partners L.P.

9.91%

RA Capital Management, LP

9.77%

Goldman Sachs & Company, Inc.

8.01%

BlackRock Institutional Trust Company, N.A.

6.67%

The Vanguard Group, Inc.

5.86%

他の

59.78%

株主統計

比率

BVF Partners L.P.

9.91%

RA Capital Management, LP

9.77%

Goldman Sachs & Company, Inc.

8.01%

BlackRock Institutional Trust Company, N.A.

6.67%

The Vanguard Group, Inc.

5.86%

他の

59.78%

種類

株主統計

比率

Investment Advisor

20.61%

Investment Advisor/Hedge Fund

19.76%

Hedge Fund

17.65%

Research Firm

14.80%

Venture Capital

14.73%

Individual Investor

3.85%

Sovereign Wealth Fund

0.12%

Bank and Trust

0.11%

Pension Fund

0.09%

他の

8.28%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

351

46.37M

100.09%

-13.01M

2025Q1

358

46.38M

99.71%

-13.16M

2024Q4

357

49.60M

107.13%

-13.93M

2024Q3

350

60.77M

117.85%

-4.39M

2024Q2

340

60.30M

117.01%

-2.54M

2024Q1

324

59.47M

116.84%

+10.27M

2023Q4

284

45.54M

106.82%

-1.53M

2023Q3

275

45.63M

108.12%

-4.94M

2023Q2

263

44.82M

109.79%

-393.70K

2023Q1

254

34.42M

103.72%

-2.13M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

BVF Partners L.P.

4.56M

9.85%

+1.89M

+70.79%

Mar 31, 2025

RA Capital Management, LP

4.56M

9.85%

--

Mar 31, 2025

Goldman Sachs & Company, Inc.

3.75M

8.09%

-81.59K

-2.13%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

3.53M

7.63%

-321.37K

-8.34%

Mar 31, 2025

The Vanguard Group, Inc.

2.76M

5.95%

-97.19K

-3.40%

Mar 31, 2025

Novo Holdings A/S

1.95M

4.21%

+450.00K

+30.00%

Mar 31, 2025

Janus Henderson Investors

1.89M

4.08%

-360.31K

-16.00%

Mar 31, 2025

Kirn (David)

1.66M

3.58%

-360.00

-0.02%

Apr 24, 2025

Federated MDTA LLC

1.24M

2.68%

+1.24M

+32944.58%

Mar 31, 2025

Millennium Management LLC

1.63M

3.53%

+213.26K

+15.01%

Mar 31, 2025

詳細を見る

7.100USD

4D Molecular Therapeutics Inc

7.100

概要

企業名

金融

分析